Business
COO & Board Appointment
COO & Board Appointment.
About this update from Gunsynd Plc
[{"type":"text","content":"\n Syntopix Group plc\n26 June 2006\n\n\nFor immediate release 26 June 2006\n\n\n SYNTOPIX GROUP PLC\n ('Syntopix' or 'the Company')\n\n APPOINTMENT OF CHIEF OPERATING OFFICER\n\n\nSyntopix Group plc (AIM: SYN), the drug discovery and development company\nfocused on dermatological diseases, is pleased to announce that Stephen Philip\nJones BSc (Hons) Pharm, PhD, MRPharmS, has been appointed to the Company and\nwill join the Board on 1 July 2006 in the newly formed position of Chief\nOperating Officer.\n\nStephen, aged 48, is a highly experienced pharmaceutical industry executive with\na track record in both branded medicines and consumer healthcare and a\nsuccessful history of new product development. At Syntopix, he will co-ordinate\noperational activities and commercial relationships.\n\nStephen was most recently at GlaxoSmithKline (GSK) where he held the position of\nVice President and Director of Consumer Healthcare Research and Development.\nStephen joined GSK in 1997 as a Senior Director of New Product Development where\nhe was responsible for sixty staff and for the development of semi-solid dosage\nforms. Prior to joining GSK Stephen worked for companies including Scherer Drug\nDelivery Systems, Sterling Winthrop, Beecham Pharmaceuticals Research Division,\nMerck Sharp & Dohme and Amersham International.\n\nStephen is a pharmacist by training, and his PhD in Pharmaceutical Sciences is\nfrom the University of Nottingham.\n\nCommenting on the appointment, Rod Adams, Syntopix' Chief Executive Officer,\nsaid: 'I am delighted that Steve has chosen to join the team at Syntopix and\nthat we have been able to attract someone of his calibre to our business.\nStephen brings to the Company an excellent track record in drug development and\nconsumer healthcare which we believe will help drive our business forward.'\n\nThe Company has today granted, for nil consideration, 289,472 options over\nordinary shares of 10p each ('Ordinary Shares') to Stephen Jones, representing\n5% per cent of the Company's current issued share capital. These options vest\nsubject to Dr Jones meeting certain performance criteria and will become\nexercisable at an exercise price of 180p per Ordinary Share between two years\nand ten years after vesting. Dr Jones' option holding following this\nnotification is 289,472.\n\nThere are no further disclosures t...